Do weight-loss drugs reduce need for CPAP? Modestly, according to new research
By HME News Staff
Updated 9:18 AM CST, Tue December 30, 2025
YARMOUTH, Maine – Popular weight-loss drugs, especially tirzepatide, are linked to modestly lower CPAP initiation among adults with Type 2 diabetes and obstructive sleep apnea (OSA), according to a research letter in the Journal of the American Medical Association (JAMA). Researchers found a stronger link between the drugs and reduced hospitalization and mortality. “These findings align with recent randomized clinical trials showing that incretin receptor agonists (IRAs), especially tirzepatide, improved OSA severity, potentially through weight loss and metabolic or respiratory mechanisms,” researchers wrote. “The modest effect size for IRAs suggests limited clinical relevance for CPAP use alone, but reductions in mortality and hospitalization support broader cardiometabolic benefits. Notably, tirzepatide showed greater reductions in risk of CPAP use and mortality than GLP-1RAs, highlighting its potential therapeutic advantage.” Researchers said future research should clarify causal pathways linking pharmacologic weight loss with OSA outcomes.
Comments